NCT06652321

Brief Summary

To evaluate the clinical outcomes (pos toperative best corrected visual acuity, endothelial count) and anatomical results (interface smoothness) of DSAEK with Femto LDV-prepared grafts from the endothelial side.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
15

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Jan 2022

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2022

Completed
2.6 years until next milestone

First Submitted

Initial submission to the registry

August 22, 2024

Completed
2 months until next milestone

First Posted

Study publicly available on registry

October 22, 2024

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 30, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 30, 2024

Completed
Last Updated

October 22, 2024

Status Verified

August 1, 2024

Enrollment Period

2.9 years

First QC Date

August 22, 2024

Last Update Submit

October 18, 2024

Conditions

Outcome Measures

Primary Outcomes (2)

  • Best spectacle-corrected visual acuity

    Measurement Tool: Snellen chart Unit of Measure: LogMAR

    after 3 and 6 months

  • Endothelial cell count using specular microscopy

    Measurement Tool: Specular microscopy Time Frame: After 3 months and 6 months

    after 3 and 6 months

Secondary Outcomes (2)

  • Total central corneal thickness (CCT)

    after 3 and 6 months

  • Donor Corneal Endothelial Thickness (CET)

    After 3 months and 6 months

Study Arms (1)

Inverted DSAEK

EXPERIMENTAL
Procedure: Endothelial Side Up Femtosecond Laser Assisted DSAEK

Interventions

The Femto LDV Z8 laser system will be set to create a 100 μm thick graft with a 7.5 mm diameter. The graft will be inverted, placed endothelial side up in the anterior chamber, and coated with Viscoat. A fixation ring will center the graft by holding the scleral rim with forceps. After cutting, the cornea should remain endothelium-up, stained with Trypan Blue, and dissected using a blunt spatula. The graft will be placed on a Busin glide and coated with Viscoat. A 3-4 mm corneal incision will be made, and Descemet's membrane will be marked and stripped. The graft will be inserted using the Busin glide, spreading automatically. A small air bubble will fill the anterior chamber to compress the graft for 10 minutes.

Inverted DSAEK

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Patients with Fuchs' endothelial dystrophy Patients with bullous keratopathy secondary to intraocular surgeries, iridocorneal endothelial syndrome, or viral keratitis

You may not qualify if:

  • Bullous keratopathy secondary to glaucoma or ocular trauma Corneal stromal scarring or opacities Diseases not affecting the corneal endothelium, including corneal ectasia (e.g., keratoconus, keratoglobus, pellucid marginal degeneration) Epithelial, Bowman layer/anterior stromal, and stromal dystrophies Hypotonic eyes Retinal diseases Any type of optic atrophy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Dar el Oyoun

Giza, Egypt

RECRUITING

MeSH Terms

Conditions

Fuchs' Endothelial Dystrophy

Condition Hierarchy (Ancestors)

Corneal Dystrophies, HereditaryCorneal DiseasesEye DiseasesEye Diseases, HereditaryGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and Abnormalities

Central Study Contacts

Tarek H Nasr, Msc

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Research Associate

Study Record Dates

First Submitted

August 22, 2024

First Posted

October 22, 2024

Study Start

January 1, 2022

Primary Completion

November 30, 2024

Study Completion

November 30, 2024

Last Updated

October 22, 2024

Record last verified: 2024-08

Data Sharing

IPD Sharing
Will share

Locations